📈 Why This Category Exploded in 2026

Blood pressure is the most frequently taken measurement in medicine, and yet most people only get it checked occasionally, at a doctor’s office — a snapshot that doesn’t reflect how much blood pressure genuinely varies throughout a normal day. Continuous, convenient measurement is a real, legitimate goal, and it’s part of why roughly 119.9 million US adults — nearly half the adult population, per CDC figures — living with high blood pressure represent such a large potential market for this technology.

This variability is worth taking seriously rather than treating as a footnote: a single office reading can be skewed upward by “white coat syndrome” — genuine anxiety in a clinical setting — or fail to capture elevated readings that only show up during exercise, poor sleep, or stress at other points in the day. Continuous or frequent monitoring genuinely could close that gap in a meaningful way, which is exactly why the category has attracted serious clinical interest alongside the current wave of consumer hype — the underlying problem it’s trying to solve is real, even where the current generation of products falls short of solving it reliably.

What actually triggered 2026’s wave of new products, though, was regulatory, not technical: the FDA relaxed its general wellness device oversight earlier in the year, and reporting from STAT News in May 2026 described the resulting shift bluntly — wearables with unvetted blood pressure measuring technology “flooding the market” from major brands including Oura and Samsung, with experts warning the devices may mislead users. Understanding that this is a recent, specifically regulatory-driven wave — not a sign the underlying accuracy problem has been solved — is the single most important piece of context for evaluating anything in this category right now.

🔬 Three Technologies, All Called “Cuffless”

Marketing copy across this category uses “cuffless blood pressure” to describe at least three meaningfully different approaches, and conflating them is where most consumer confusion starts.

Oscillometric — a real, miniature cuff, just built into the band

Devices like the Omron HeartGuide and Huawei Watch D use the same fundamental principle as a doctor’s cuff — a small inflatable band that detects pressure changes directly — just shrunk down to fit a wrist band. This is the most accurate approach available in a wearable, and it’s genuinely a bit misleading to call these “cuffless” at all, since they still use a cuff — just a much smaller one.

PPG / Pulse Transit Time (PTT) — genuinely no cuff, but needs one periodically

Devices like the Aktiia Hilo Band and Samsung Galaxy Watch use optical sensors (photoplethysmography) to detect blood flow changes at the wrist, either alone or combined with pulse transit time between two points, to estimate blood pressure. This is genuinely cuffless in daily use, but every device using this method requires periodic calibration against a real cuff — Samsung specifies every 28 days — because the relationship between the optical signal and actual blood pressure drifts over time without it.

ML-inferred trends — not a blood pressure measurement at all

WHOOP’s “Blood Pressure Insights” beta feature doesn’t measure blood pressure directly — it infers trends using a machine learning model built from heart rate, HRV, PPG signal, and user-entered reference values, producing directional estimates rather than an absolute reading. Some smart rings marketed with blood pressure claims fall into a similar or even less rigorous category — as of 2026, no major smart ring directly measures blood pressure; claims are based on indirect HRV-derived estimation, which independent reviewers rate as less accurate than even PPG smartwatch methods.

⚖️ The Regulatory Story: What Actually Changed

In July 2025, the FDA cleared the Aktiia Hilo Band as the first cuffless blood pressure monitor authorized for over-the-counter use — a genuine, formal milestone supported by clinical trials comparing it against reference devices including arterial catheters, with demonstrated accuracy across a range of skin tones and body positions.

On January 23, 2026, the FDA issued draft guidance titled “Cuffless Non-invasive Blood Pressure Measuring Devices — Clinical Performance Testing and Evaluation,” intended to clarify the evidence bar for future devices. This guidance is not yet final; the public comment period closed March 24, 2026, and the finished version was still pending as of this writing.

In the same period, the FDA updated its broader General Wellness policy in a way that created real ambiguity: products using sensors to estimate physiological parameters — including blood pressure — can potentially qualify as general wellness products, exempt from the stricter clinical evidence bar, when marketed solely for wellness purposes rather than diagnosis. This is the specific regulatory opening that allowed companies like Oura and Samsung to move into blood pressure features more quickly than the formal medical-device clearance pathway would otherwise allow.

📱 Real Devices, By Category

Aktiia Hilo Band — The Only True OTC-Cleared Cuffless Device

The Hilo Band is the first and, as of this writing, only cuffless blood pressure wearable with genuine FDA over-the-counter clearance. It uses PPG at the wrist, requires monthly calibration, can be worn day and night for up to 50 measurements a day, costs roughly $280, and became available to patients in 2026. Free access covers the most recent 7 days of data; a paid membership unlocks full history and deeper trend analysis.

Samsung Galaxy Watch (7, 8, Active) — PPG/PTT With Mandatory Cuff Calibration

Samsung’s blood pressure feature, now available to US users through Samsung Health, requires calibration against a separately purchased upper-arm cuff every 28 days. Samsung’s own product messaging is explicit that “the Blood pressure monitoring feature is not intended to prevent or diagnose high blood pressure” — a notable disclaimer directly from the manufacturer, worth taking at face value rather than assuming marketing enthusiasm elsewhere in the product page overrides it.

Omron HeartGuide & Huawei Watch D — Miniature Cuff, Best Wearable Accuracy

Omron HeartGuide remains the wrist-worn device with the strongest clinical validation, using a genuine oscillometric mini-cuff. It’s bulkier and pricier (often $400+) than PPG alternatives, and by 2026 is considered somewhat dated in smartwatch features compared to newer competitors — but for anyone prioritizing accuracy over convenience, it remains the most trusted wearable option. Huawei’s Watch D and D2 use a similar mini-cuff approach with comparable accuracy claims.

WHOOP Blood Pressure Insights — Trend Estimates, Not Measurements

WHOOP’s beta feature explicitly does not measure blood pressure directly. It infers directional trends from HRV, heart rate, and PPG data combined with a user-entered reference reading. Treat this as a trend signal layered onto WHOOP’s existing recovery metrics, not a number to report to a doctor.

What About Smart Rings?

As of 2026, no major smart ring — including Oura and RingConn — directly measures blood pressure, despite marketing language that sometimes implies otherwise. Ring-based blood pressure claims are built on indirect HRV estimation, a method independent reviewers consistently rate as less accurate than even PPG-based smartwatch approaches. If blood pressure specifically is your priority, a ring is currently the weakest category to rely on regardless of brand.

📊 Quick Comparison

🎯 The Accuracy Reality Check

Real-world accuracy data across this category tells a consistent story: cuff-based approaches, even miniaturized ones, outperform optical methods, and optical methods degrade meaningfully without frequent recalibration. PPG-based watches can be accurate immediately after a fresh calibration but often drift 10–15 mmHg or more within days; cuff-based wearables typically show a tighter 5–10 mmHg deviation from a standard arm cuff when properly maintained.

There’s also an existing technical standard worth knowing about: IEEE 1708-2014 defines performance requirements specifically for wearable cuffless blood pressure devices. Its existence for over a decade, alongside the FDA’s 2026 draft guidance still being finalized, illustrates how much of this category has been operating ahead of settled, universally-applied accuracy standards.

A device being available to buy is not the same as a device being validated for the decision you’re using it to make. That distinction matters more in this category than almost any other consumer wearable category, because the downside of a wrong number — delayed treatment or unnecessary alarm — is genuinely serious.

It’s also worth understanding why optical methods drift in the first place, rather than treating it as an arbitrary limitation. PPG and PTT approaches don’t measure pressure directly — they infer it from how light absorption or pulse timing changes at the wrist, then apply a model calibrated to your specific cardiovascular characteristics at the moment of calibration. As factors like arterial stiffness, hydration, temperature, and simple day-to-day physiological variation shift, that calibration becomes progressively less representative of your current state — which is precisely why periodic recalibration against a real cuff isn’t a minor inconvenience bolted onto the technology, but a structural requirement of how it works at all. A device that soft-pedals or omits this requirement in its marketing is omitting the single most important caveat for interpreting its numbers correctly.

🚩 Red Flags in BP Wearable Marketing

• “Cuffless” used without specifying the underlying technology — oscillometric, PPG, or ML-inferred trend are very different claims wearing the same marketing word
• Smart ring blood pressure claims — no major ring directly measures blood pressure as of 2026, regardless of how the feature is marketed
• “FDA cleared” presented as “clinically proven accurate” — the AHA has explicitly stated clearance doesn’t require standardized accuracy testing
• No mention of a calibration requirement for any PPG or PTT-based device — if calibration isn’t disclosed clearly, treat the accuracy claims skeptically
• Marketing that implies the device can replace a doctor’s diagnosis — the AHA’s position is explicit that none of these should currently be used for diagnosis or treatment decisions

⚠️ Common Mistakes

Skipping the calibration schedule on a PPG-based device. Without it, drift of 10–15 mmHg or more is common — a meaningfully large error for a health metric where the difference between normal and elevated can be a similar margin.

Treating a wearable reading as equivalent to a doctor’s office measurement. Even the most accurate wearables are best used for trend awareness alongside, not instead of, periodic validated cuff measurements.

Buying a smart ring specifically for blood pressure tracking. This is currently the least accurate category for this specific purpose, regardless of brand marketing.

Making medication or treatment decisions based on wearable readings alone. This directly contradicts the AHA’s explicit guidance and should always go through a healthcare provider using validated measurement.

Assuming newer means more accurate. The 2026 wave of new entrants exists partly because of relaxed regulatory oversight, not necessarily because the underlying accuracy problem has been solved — a newer product isn’t automatically a more validated one.

✅ Who Actually Benefits

• People already diagnosed with hypertension who want additional trend data points between validated cuff readings, not a replacement for them
• Anyone curious about how blood pressure varies across a day or with activity, viewed as a wellness signal rather than a diagnostic one
• People specifically prioritizing accuracy over convenience, for whom a miniature-cuff device like Omron HeartGuide is worth the bulk
• Early adopters comfortable with genuine uncertainty in a fast-moving, not-yet-fully-regulated category

This category is a poorer fit if you’re looking for a device to replace clinical diagnosis or guide medication changes on its own — the AHA’s guidance is explicit that none of these tools are validated for that use yet.

🚀 How to Get Started Safely

1. Identify the actual technology behind any device you’re considering — oscillometric, PPG/PTT, or ML-inferred — before comparing accuracy claims.
2. If choosing a PPG or PTT device, commit to the calibration schedule from day one; treat a missed calibration window as a reason to distrust readings until you recalibrate.
3. Keep using a validated cuff-based monitor for any reading that actually matters — a doctor’s appointment, a medication change discussion, or genuine concern about a symptom.
4. Track trends over weeks, not single readings, and bring that trend data to a healthcare provider rather than interpreting it alone.
5. Watch for the FDA’s finalized cuffless BP guidance, expected sometime after the March 2026 comment period closed — the accuracy bar for new devices may shift once it’s finalized.

❓ Frequently Asked Questions

Is any cuffless blood pressure wearable actually FDA-cleared?

Yes — the Aktiia Hilo Band, cleared for over-the-counter use in 2025 and available to patients in 2026. It remains the clearest example of a genuinely validated cuffless device as of this writing, though FDA clearance itself doesn’t guarantee accuracy under a standardized protocol per the American Heart Association.

Can Oura Ring or other smart rings measure blood pressure?

No major smart ring directly measures blood pressure as of 2026. Any blood pressure-related claims are based on indirect HRV estimation, which is less accurate than even PPG-based smartwatch methods.

Why does Samsung’s Galaxy Watch need a cuff to work?

Its PPG/PTT-based estimation requires periodic calibration against a real blood pressure cuff, roughly every 28 days, because the relationship between the optical signal and actual blood pressure drifts over time without recalibration.

Should I use a wearable instead of my regular blood pressure monitor?

No. The American Heart Association’s current position is that cuffless devices should not be used to diagnose, track, or treat high blood pressure. Use a validated cuff-based monitor for anything that actually informs a medical decision.

Why did so many new blood pressure wearables launch in 2026?

The FDA relaxed general wellness device oversight in early 2026, which allowed companies to add blood pressure features under wellness marketing rather than the stricter medical-device clearance pathway, leading to a rapid increase in new products.

💡 Final Thoughts

Cuffless blood pressure wearables are a genuinely promising category moving faster than the science and regulation supporting it. One device — the Aktiia Hilo Band — has real FDA over-the-counter clearance; several others use a real, if miniaturized, cuff; and a growing number make blood pressure-adjacent claims built on indirect estimation that shouldn’t be mistaken for measurement. The American Heart Association’s guidance is worth holding onto through all of this year’s new launches: useful as a wellness trend signal, not yet ready to replace a validated cuff for any decision that actually matters.

For more on how wearable accuracy and marketing claims play out in other health categories, see our recovery tech coverage and testosterone and hormone optimization guide.